256 results on '"Terragna, C."'
Search Results
2. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
3. High Level of Circulating Tumour DNA at Diagnosis Correlates With Disease Spreading and Defines Multiple Myeloma Patients With Poor Prognosis
4. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis
5. S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS
6. P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN
7. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
8. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia
9. : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
10. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
11. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
12. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
13. Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures
14. Pathways Shared by t(4;14) and D13 positive MM Patients Impact Response to Velcade/Thalidomide/Dexamethasone: B497
15. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely
16. Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)
17. PS1346 CLONAL EVOLUTION IN MULTIPLE MYELOMA PATIENTS RECEIVING MAINTENANCE THERAPY
18. PF560 A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS
19. Characterization of a new HLA-DRB5 allele (DRB5*0105) by PCR-SSP and direct sequencing
20. Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient
21. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
22. Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients
23. Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial
24. Multiple myeloma: disease response assessment
25. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
26. Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8]
27. HIGH SOKAL RISK IN CHRONIC MYELOID LEUKEMIA PATIENTS AT DIAGNOSIS SHOWED THE ELEVATED EXPRESSION OF FBP1, A KEY-ENZYME OF GLUCONEOGENESIS
28. Hedgehog Pathway Over Expression Identifies Myeloma Patients With Worse Prognosis
29. DISSECTING MOLECULAR BASES OF HIGH SOKAL VERSUS LOW SOKAL RISK IN CHRONIC MYELOID LEUKEMIA PATIENTS BY GENE EXPRESSION PROFILES OF CD34+ CELLS AT DIAGNOSIS
30. RESPONSE TO VELCADE-THALIDOMIDE-DEXAMETHASONE (VTD) AS INDUCTION TERAPHY IN MULTIPLE MYELOMA PATIENTS CARRYING T(4;14): ANALYSIS OF GENE EXPRESSION PROFILE
31. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study
32. CD34+ from high Sokal risk chronic myeloid leukaemia patients expresses gene profi le signifi cantly different from CD34+ obtained from low and intermediate Sokal risk pts: a subgroup of CML pts candidate to upfront search for BMT donor?
33. Final analysis of the multicenter phase II 'Bologna 2002' study incorporating thalidomide-dexamethasone (thal-dex) into up-front double autologous stem-cell transplantation (ASCT) for multiple myeloma
34. Detection of bcr-abl transcript in chronic myelogenous leukemia by reverse-transcription-polymerase chain reaction and capillary electrophoresis
35. INCORPORATION OF THALIDOMIDE INTO UP-FRONT DOUBLE AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA: PROGNOSTIC RELEVANCE OF BASELINE CYTOGENETIC ABNORMALITIES
36. Down regulation of TOPK, PBX3, SRPK, DDX21 and CLC genes in newly diagnosed early chronic phase chronic myeloid leukemia ptients treated with imatinib mesylate
37. A new abl kinase inhibitor (AMN107) has in vitro activity on CML Ph plus Blast cells resistant to imatinib
38. A novel 4-anilino-3-quinolinecarbonitrile dual sre and AbI kinase inhibitor (SKI-606) has in vitro activity on CML Ph plus Blast cells resistant to imatinib
39. Molecular therapy of AML: a new and rapid method to characterize novel genetic variants in FLT3 gene
40. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
41. Rapid detection of FLT3 mutations in acute myeloid leukemia patients by denaturing high-performance liquid chromatography
42. Molecular therapy of AML: a new and rapid method to characterize novel genetic variants of Flt3 gene
43. AML1-ETO trabscript expression patterns in acute myeloid leukemia patients with t(8;21) in complete haematological remission
44. Hypereosinophilic sindrome treated with imatinib therapy: clinical and biological analysis
45. Other targets for Imatinib therapy
46. Real time quantification of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate arisk for clinical relapse and may identify patients in curable state
47. Rapid detection of Flt3-ITD in acute myeloid leukemia patients by DF-HPLC
48. Real-time quantification of minimal residual disease in inv(16) positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
49. Rare CBFbeta-MYH11 fusion transcripts in patients with acute myeloid leukemia associated with inversion of chromosome 16
50. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha based therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.